Abstracts

Distinct Intestinal Microbial Signatures Linked to Accelerated Biological Aging in People With HIV

Background: HIV infection disrupts the intestinal barrier, resulting in persistent inflammation, even with antiretroviral therapy (ART). This inflammation contributes to aging-related comorbidities in people with HIV (PWH). However, it remains unclear whether ART-suppressed HIV affects intestinal biological aging and whether microbial dysbiosis and translocation contribute to aging in PWH on ART. Methods: Colon and ileal…

Herpesviruses Reactivation and Associated Systemic Inflammation During Initiating ART, Rakai-Uganda

Background: We conducted a prospective observational study to evaluate HSV-2, Cytomegalovirus (CMV), and HHV-8 herpesviruses shedding after ART initiation and associated markers of systemic inflammation in women living with HIV (WLWH). Methods: We recruited 187 WLWH not on ART, aged ≥18 years from three HIV/ART clinics in south-central Uganda. CMV and HSV-2 shedding was quantified…

B-Cells Augment HIV-1 Expression in Secondary Lymphoid Tissues

Background: HIV-expressing (vRNA+) cells are consistently found in secondary lymphoid tissues (SLT) of people with HIV (PWH) on antiretroviral therapy (ART) and likely drive viral rebound upon ART cessation. Little is known about what affects HIV expression in SLT. We hypothesized that B cells promote HIV expression. Methods: Disaggregated tonsil cells from persons without HIV…

Genetic Variants Associated to HIV Control Are Associated With NK Cell Markers and Response to CMV

Background: Genome-wide association studies (GWAS) have shown that genetic variants in the MHC region are associated with spontaneous HIV-1 control. How these variants affect immune functioning is, however, poorly understood. We used a functional genomics approach in which we integrated GWAS with transcriptomic, plasma proteomic and functional immunological data to understand how genetics contribute to…

Impact of Capsid Polymorphisms on Viral Fitness and the Susceptibility to Lenacapavir

Background: Lenacapavir (LEN) is a first-in-class, long-acting capsid (CA) inhibitor for the treatment and prevention of HIV-1 infection. While LEN has shown full potency against different HIV-1 subtypes, it remains unclear how viral diversity encountered in the clinic may impact its efficacy. Herein we analyzed HIV-1 CA sequence diversity to identify natural polymorphisms within the…

No Early Signal That DTG Improves 24-Week Viral Suppression in Infants in Botswana

Background: The World Health Organization recommends dolutegravir (DTG)-based 3-drug antiretroviral therapy (ART) in children >4 weeks weighing >3kg. DTG-based ART achieves rapid viral load decline in adults and low rates of treatment failure in older children, but outcomes for children treated from birth, a time when adherence challenges are of particular concern, are limited. Methods:…